The Financial Times notes that Merck's Januvia could be approved by the FDA as early as today. Januvia is a new type of diabetes drug that regulates sugar and insulin production. Analysts expect Januvia to be a blockbuster, which would be a welcome relief to the embattled Merck. But Merck won't own the DPP-IV inhibitor market for long. Novartis' Galvus is expected to get an approval next month.
- here's the report [1] from MarketWatch on Januvia
PLUS: An approval will trigger widespread use. Report [2]
ALSO: Pfizer and Eisai won U.S. regulatory approval to expand the use of Aricept to more serious cases of Alzheimer's. Report [3]
Related Article:
ADA meeting sees new data on diabetes drugs. Report [4]
Links:
[1] http://www.marketwatch.com/News/Story/Story.aspx?dist=newsfinder&siteid=mktw&guid=%7BABFFA721-311E-4476-B784-28D6AF3ECCC6%7D
[2] http://www.signonsandiego.com/news/health/20061016-0740-health-diabetes.html
[3] http://today.reuters.com/news/articleinvesting.aspx?type=governmentFilingsNews&storyID=2006-10-16T121242Z_01_WEN7021_RTRIDST_0_HEALTH-PFIZER-URGENT.XML
[4] http://www.fiercebiotech.com/story/ada-meeting-sees-new-data-on-diabetes-drugs/2006-06-12